

Title (en)
METASTABLE PHARMACEUTICAL COMPOSITIONS

Title (de)
METASTABILE PHARMAZEUTISCHE ZUSAMMENSETZUNGEN

Title (fr)
COMPOSITIONS PHARMACEUTIQUES METASTABLES

Publication
EP 1531867 A4 20110323 (EN)

Application
EP 03729714 A 20030624

Priority
• AU 0300785 W 20030624
• AU PS317302 A 20020625

Abstract (en)
[origin: WO2004000361A1] The present invention provides a pharmaceutical composition for transdermal delivery comprising; one or more physiologically active agents; and a volatile pharmaceutically acceptable solvent; and wherein the physiological active agent forms a metastable deposit upon evaporation of the volatile solvent.

IPC 1-7
A61K 47/10; **A61K 9/06**; **A61K 31/568**; **A61K 31/565**; **A61K 31/435**; **A61K 31/496**; **A61P 15/10**; **A61P 15/18**; **A61P 25/04**; **A61P 25/22**

IPC 8 full level
A61K 9/12 (2006.01); **A61K 9/70** (2006.01); **A61K 31/137** (2006.01); **A61K 31/165** (2006.01); **A61K 31/216** (2006.01); **A61K 31/4025** (2006.01); **A61K 31/4045** (2006.01); **A61K 31/4196** (2006.01); **A61K 31/435** (2006.01); **A61K 31/4468** (2006.01); **A61K 31/473** (2006.01); **A61K 31/496** (2006.01); **A61K 31/506** (2006.01); **A61K 31/565** (2006.01); **A61K 31/567** (2006.01); **A61K 31/568** (2006.01); **A61K 47/06** (2006.01); **A61K 47/10** (2006.01); **A61K 47/32** (2006.01); **A61K 47/38** (2006.01); **A61M 11/00** (2006.01); **A61P 5/24** (2006.01); **A61P 13/10** (2006.01); **A61P 15/10** (2006.01); **A61P 15/18** (2006.01); **A61P 25/02** (2006.01); **A61P 25/04** (2006.01); **A61P 25/06** (2006.01); **A61P 25/08** (2006.01); **A61P 25/16** (2006.01); **A61P 25/18** (2006.01); **A61P 25/22** (2006.01); **A61P 29/00** (2006.01); **A61P 29/02** (2006.01)

CPC (source: EP KR)
A61K 9/0014 (2013.01 - EP); **A61K 9/06** (2013.01 - KR); **A61K 9/7015** (2013.01 - EP); **A61K 31/435** (2013.01 - EP); **A61K 31/496** (2013.01 - EP); **A61K 31/565** (2013.01 - EP KR); **A61K 31/567** (2013.01 - EP); **A61K 31/568** (2013.01 - EP KR); **A61K 47/10** (2013.01 - EP KR); **A61K 47/32** (2013.01 - EP); **A61K 47/38** (2013.01 - EP); **A61P 5/24** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 15/10** (2017.12 - EP); **A61P 15/18** (2017.12 - EP); **A61P 25/02** (2017.12 - EP); **A61P 25/04** (2017.12 - EP); **A61P 25/06** (2017.12 - EP); **A61P 25/08** (2017.12 - EP); **A61P 25/16** (2017.12 - EP); **A61P 25/18** (2017.12 - EP); **A61P 25/22** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 29/02** (2017.12 - EP)

Citation (search report)
• [X] WO 0102015 A1 20010111 - UNIV GEORGIA RES FOUND [US]
• [XA] WO 9206675 A1 19920430 - MINNESOTA MINING & MFG [US]
• [X] EP 0803254 A1 19971029 - LUITPOLD PHARMA GMBH [DE]
• See references of WO 2004000361A1

Designated contracting state (EPC)
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PT RO SE SI SK TR

DOCDB simple family (publication)
WO 2004000361 A1 20031231; AU PS317302 A0 20020718; BR 0312003 A 20050322; CA 2490057 A1 20031231; EA 012648 B1 20091230; EA 200500083 A1 20050825; EP 1531867 A1 20050525; EP 1531867 A4 20110323; JP 2005534670 A 20051117; JP 2010248250 A 20101104; KR 20050120726 A 20051223; NZ 537436 A 20070126

DOCDB simple family (application)
AU 0300785 W 20030624; AU PS317302 A 20020625; BR 0312003 A 20030624; CA 2490057 A 20030624; EA 200500083 A 20030624; EP 03729714 A 20030624; JP 2004514438 A 20030624; JP 2010172167 A 20100730; KR 20047020966 A 20041223; NZ 53743603 A 20030624